|

RLY-2608 Clinical Trials

2 actively recruiting trials across 2 locations

Pipeline

Phase 1: 1Phase 3: 1

Top Sponsors

  • Relay Therapeutics, Inc.2

Indications

  • PIK3CA Mutation2
  • Metastatic Breast Cancer2
  • HER2-negative Breast Cancer2
  • Advanced Breast Cancer2
  • Breast Cancer2

Gilbert, Arizona1 trial

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

Banner MD Anderson Cancer Center

Phase 3

Tucson, Arizona1 trial

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

The University of Arizona Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.